Skin Elements Limited has secured a $900,000 placement at a 25% discount to recent prices, bolstering its balance sheet to advance its natural biotechnology product range. The company also appointed Rod Nicholas as non-executive chairman and engaged Phoenix Global Investments for investor relations.
- Placement of 300 million shares at $0.003 each
- 25% discount to last closing price
- Funds to support ECO Nurture, SuprCuvr, Soleo Organics, PapayaActivs
- Rod Nicholas appointed non-executive chairman
- Phoenix Global Investments engaged for investor relations
Capital Raise Strengthens Skin Elements’ Financial Position
Skin Elements Limited (ASX:SKN) has secured firm commitments to raise $900,000 through a placement of 300 million shares priced at $0.003 each. This price represents a 25% discount to the company’s last closing price of $0.004 on 24 June 2026 and a 32.8% discount to the five-day volume weighted average price (VWAP) of $0.0045. Settlement of the placement shares is expected by 16 July 2026.
The capital injection aims to bolster Skin Elements’ balance sheet and provide working capital to advance its portfolio of natural biotechnology products. These include the ECO Nurture plant bio-stimulant, SuprCuvr hospital-grade disinfectant, Soleo Organics sunscreen, and the PapayaActivs therapeutic skincare range. The company emphasised that the funds will also support evaluation of development opportunities and general working capital needs.
Leadership Changes and Board Remuneration Adjustments
In a notable governance update, Skin Elements appointed Mr Rod Nicholas as non-executive chairman, effective 23 June 2026. Concurrently, the company reviewed its board remuneration structure, reducing the annual base fee for non-executive directors to $48,000 and setting the chairman’s fee at $60,000 per annum. These moves appear aimed at aligning leadership costs with the company’s current scale and strategic priorities.
Investor Relations Partnership with Placement Manager
Skin Elements has engaged Phoenix Global Investments Pty Ltd, which acted as sole lead manager for the placement, to provide public and investor relations services for a 12-month term. As part of this agreement, Phoenix will receive 25 million fully paid shares at the placement price of $0.003 per share, subject to a 12-month voluntary escrow. Phoenix is also entitled to a 6% fee on the gross proceeds of the placement, payable in cash or shares.
By tying investor relations to the placement manager, Skin Elements is signalling a coordinated approach to capital markets engagement. This may help the company maintain momentum in raising its profile and supporting shareholder communications as it advances its product pipeline.
Implications for Shareholders and Next Steps
The discounted placement dilutes existing shareholders but provides essential capital for Skin Elements to continue developing its niche in natural biotechnology. The company’s focus on sustainability and plant-based formulations positions it within growing consumer and commercial markets for organic and therapeutic skincare and disinfectants.
Investors will be watching how effectively Skin Elements deploys this capital to progress product development and commercialisation, especially given the company's recent governance changes. The timing of share issuance and the integration of Phoenix Global Investments’ investor relations efforts will be key factors to monitor in the coming months.
Bottom Line?
Skin Elements’ $900K placement at a significant discount bolsters its runway but raises questions about execution and shareholder dilution ahead.
Questions in the middle?
- How will the discounted placement impact Skin Elements’ share price and liquidity post-settlement?
- What milestones or commercial deals can shareholders expect as Skin Elements advances its product programs?
- How effective will the new chairman and investor relations partnership be in driving strategic growth?